NXL Nexalin Technology
- 1.3212
- -0.0488-3.56%
Nexalin Technology News
Nexalin Technology First Quarter 2024 Earnings: US$0.14 Loss per Share (Vs US$0.10 Loss in 1Q 2023)
10-Q: Quarterly report
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on May 23
HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m. ET. The exclusive event,
Nexalin Technology Has Received A Notice Of Allowance For Its U.S. Patent Application 18/342,590 Titled "Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method For Alzheimers And Dementia"
Nexalin Technology Has Received A Notice Of Allowance For Its U.S. Patent Application 18/342,590 Titled "Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method For Alzheimers And
Nexalin Technology Regains Compliance With Nasdaq Continued Listing Requirements
HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) announced that the Company received notice from The Nasdaq Stock Market ("Nasdaq") on April
Predictive Oncology, BIMI Holdings, IMAC Holdings Among Healthcare Movers
LI, VERU and MRIN Among Pre-market Losers
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersChromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million. Kineta (NASDAQ:KA) stock moved upwards
Lexaria Bioscience, Biosig Technologies, BIMI Holdings Among Healthcare Movers
JAGX, BSGM and SXTC Among Mid-day Movers
Nexalin Technology Files to Offer Common Stock Worth $5.65M
Palisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics Among Healthcare Movers
Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals Among Healthcare Movers
Nexalin Technology Accelerates HALO Clarity Manufacturing; Expects To Produce ~500 Units In Q3 2024
Nexalin Technology Accelerates HALO Clarity Manufacturing; Expects To Produce ~500 Units In Q3 2024
Nexalin Technology Accelerates Manufacturing of Its HALO Clarity Following Successful Usability, Feasibility, and Electrical Testing
Mark White, CEO of Nexalin Technology, stated, "I am thrilled to report that the HALOClarity passed a series of rigorous tests, validating our manufacturing process and illustrating that our device meets the highest product standards.
12 Health Care Stocks Moving In Monday's After-Market Session
GainersKineta (NASDAQ:KA) shares increased by 24.3% to $0.67 during Monday's after-market session. The market value of their outstanding shares is at $7.3 million. Moleculin Biotech (NASDAQ:MBRX) stoc
PERI, ITRM and CADL Among Pre-market Losers
Check-Cap, Outset Medical, Vincerx Pharma Among Healthcare Movers
Nexalin Technology Awarded Key Patent Related To Gen-3 HALO Clarity
Mark White, CEO of Nexalin Technology, stated, "This method of use patent award marks a major achievement for the Company and follows another recent patent covering our core technology. These patents
Nexalin Technology Awarded Key Patent Related to Its Gen-3 HALO Clarity, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 17/337,653 relating to the Company's non-invasive, frequency-based deep brain stimulation device.
Analysis
Price Target
No Data
